Yecuris

Executive Summary

Yecuris is a preeminent preclinical research organization specializing in humanized mouse models and contract research services to accelerate drug discovery. Founded in 2007 and headquartered in Portland, Oregon, the company's core technology is the FRG® knockout platform, which enables the creation of liver-humanized mice that express functional human hepatocytes. This provides a highly physiologically relevant in vivo system for studying human drug metabolism, toxicity, infectious diseases, metabolic liver disorders, and gene therapies. Yecuris serves a broad range of pharmaceutical and biotechnology clients, offering services that reduce the attrition rate of drug candidates by bridging the gap between animal models and human outcomes. Despite being a private company with limited public financial disclosure, Yecuris has established itself as a critical partner in the drug development ecosystem, particularly for therapies targeting the liver. The company's models are essential for evaluating the safety and efficacy of novel therapeutics, including antisense oligonucleotides, gene editing tools, and viral vector-based treatments. As the demand for more predictive preclinical tools grows, Yecuris is well-positioned to expand its service offerings and client base. The lack of disclosed funding or valuation suggests a lean, self-sustaining operation, which may limit rapid scaling but underscores its niche expertise and recurring revenue from repeat collaborations.

Upcoming Catalysts (preview)

• Q3 2026Expansion of FRG Platform into New Therapeutic Areas70% success
• Q4 2026Strategic Partnership with Major Gene Therapy Developer50% success
• Q2 2026Publication of Validation Data in High-Impact Journal80% success